Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe
TILD-19-19
Phase 3 small_molecule active
Quick answer
Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe for Psoriatic Arthritis is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Psoriatic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active